Last reviewed · How we verify
Cebranopadol 1000 µg
At a glance
| Generic name | Cebranopadol 1000 µg |
|---|---|
| Also known as | Treatment Phase, Experimental |
| Sponsor | Tris Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. (PHASE1)
- Assessment of Abuse Potential of Cebranopadol in Humans (PHASE1)
- CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (PHASE3)
- CORAL XT - Open-label Extension Trial of the CORAL Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cebranopadol 1000 µg CI brief — competitive landscape report
- Cebranopadol 1000 µg updates RSS · CI watch RSS
- Tris Pharma, Inc. portfolio CI